BioCentury
ARTICLE | Clinical News

BIT225: Completed Phase II enrollment

September 2, 2013 7:00 AM UTC

In July, Biotron completed enrollment of 12 treatment-naïve patients co-infected with HIV and HCV genotype 1, 2 or 3 in an open-label, Thai Phase II trial evaluating 300 mg BIT225 once daily on days 7...